This account traces that arc: the growth hormone-releasing peptide (GHRP) tradition that made ipamorelin conceivable, its characterization at Novo Nordisk in 1998, the 1999 identification of ghrelin that redefined its target, the preclinical program that broadened its research profile, and the clinical and regulatory milestones that followed
Convenient once-daily capsule for easy supplementation
Supplementary information ESM 1 (download DOCX (DOCX 1210 kb) Rights and permissions Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made
Rahmatullah, M
This gastric slowing can also affect the absorption of some oral medications, particularly with tirzepatide, which can reduce the effectiveness of oral contraceptives
10.1016/s0021-9258(19)38603-x 127 LyuX.-D.LiuY.WangJ.WeiY
